GlassScriptPhysician profile
John C Southerland
NPI 1053305565
$15,508.61
in general payments reported to CMS, 2019-2025
47 companies · $3,107 in 2025
The $3,107 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $831 · 2021: $2,102 · 2022: $2,337 · 2023: $2,544 · 2024: $3,132 · 2025: $3,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,650 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,649.67 |
| Education | $132.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,435.79 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $2,127.71 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,253.28 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $1,188.66 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $1,034.11 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $905.49 | 2019-2025 | |
| Celgene Corporation | $471.14 | 2021-2024 | Zeposia |
| Genzyme Corporation | $408.26 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $361.40 | 2019-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $340.30 | 2023-2025 | Vowst, Zenpep |
| Ironwood Pharmaceuticals, INC | $334.56 | 2019-2025 | Linzess |
| Braintree Laboratories, INC. | $284.25 | 2019-2024 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $263.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $259.48 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $237.17 | 2022-2025 | Dupixent |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $216.35 | 2019-2024 | Cre Pro, Watchman Access System |
| Redhill Biopharma INC. | $208.90 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Ardelyx, INC. | $185.66 | 2022-2025 | Ibsrela |
| Shionogi INC | $163.85 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $158.43 | 2020-2023 | |
| Olympus America INC. | $125.41 | 2021 | |
| Merck Sharp & Dohme LLC | $109.57 | 2019-2024 | Dificid, Zinplava |
| Daiichi Sankyo INC. | $106.29 | 2019-2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $105.86 | 2024-2025 | Voquezna |
| Fresenius Kabi USA, LLC | $93.94 | 2023-2025 | Idacio, Tyenne |
| Neuraxis, INC. | $85.56 | 2025 | |
| Celltrion USA INC. | $76.17 | 2024 | Zymfentra, Vegzelma |
| Evoke Pharma, INC. | $70.74 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $67.99 | 2024 | Terlivaz |
| Ferring Pharmaceuticals INC. | $66.04 | 2019-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $65.55 | 2024 | Iqirvo, Bylvay |
| Ucb, INC. | $64.73 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $64.51 | 2022-2024 | Monoferric |
| Abiomed | $63.91 | 2024 | Impella |
| Romark Laboratories, Lc | $62.70 | 2019 | |
| Palette Life Sciences, INC. | $58.57 | 2022 | |
| Amgen INC. | $53.28 | 2023 | Avsola, Amjevita |
| Vivus LLC | $52.52 | 2021-2022 | |
| Novo Nordisk INC | $48.94 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $40.07 | 2022-2024 | Zeposia |
| Alnylam Pharmaceuticals INC. | $39.27 | 2022-2023 | Givlaari |
| Allergan, INC. | $38.34 | 2019-2020 | |
| Shire North American Group INC | $35.72 | 2019 | |
| Organon LLC | $22.80 | 2025 | Renflexis, Hadlima |
| Astrazeneca Pharmaceuticals LP | $20.28 | 2023 | Andexxa |
| Alfasigma USA, INC. | $17.41 | 2020 | |
| Stryker Corporation | $13.92 | 2025 | Procedural Oxygen Mask, Neptune |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Southerland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.